Retatrutide vs Wegovy: What's the Difference

Retatrutide and Wegovy are not two versions of the same drug. Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk that has received FDA approval for chronic weight management. Retatrutide is a different molecule entirely — an investigational triple agonist that acts on three receptors instead of one — and it is still in phase 3 trials, with no approved brand name and no FDA approval of any kind. PeptoClinic's retatrutide is research material, not a substitute for Wegovy, and it is not approved by the FDA either.

Mechanism: one receptor or three

Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist. It mimics a single gut hormone, GLP-1, that signals satiety and slows gastric emptying. That single-receptor mechanism is what Wilding et al. (NEJM, 2021) tested in the STEP 1 trial, which became the basis for the FDA's 2021 approval of Wegovy.

Retatrutide works differently. It's a triple agonist, engaging the GLP-1 receptor plus two others — GIP and glucagon receptors — in a single molecule. The rationale tested in the literature is that stacking three hormonal pathways produces effects beyond what a single-receptor drug reaches on its own. Jastreboff et al. (NEJM, 2023) ran the phase 2 trial in adults with obesity that first reported on this mechanism, and the compound has since moved into phase 3, reported by Jastreboff et al. (NEJM, 2026).

This is the core distinction a reader comparing the two should keep: Wegovy's mechanism is already proven enough to carry FDA approval and a market brand. Retatrutide's three-receptor mechanism is still being characterized in ongoing trials.

Where retatrutide stands in FDA review

Retatrutide has not been approved by the FDA, for weight loss, diabetes, or any other indication. It is currently in phase 3 trials — the stage immediately before a regulator can review a New Drug Application. The trials in progress and their enrollment status are public and searchable on ClinicalTrials.gov.

Phase 3 is further along than a compound that has only been tested in small early trials, but it is not the same thing as approval. Trials can report positive results in phase 3 and still take years to reach a regulatory decision, and some never do. Nothing in the current trial record implies an approval date, and nobody selling the molecule today — including PeptoClinic — can represent that it is approved, because it isn't.

What the obesity and diabetes trials have reported

Retatrutide's obesity data comes from two trials run in sequence. The phase 2 trial, Jastreboff et al. (NEJM, 2023), enrolled adults with obesity and reported that participants receiving retatrutide lost significantly more body weight over the trial period than those on placebo. The phase 3 trial, Jastreboff et al. (NEJM, 2026), extended that work to a larger population specifically for the obesity indication. Separately, retatrutide has also been studied in type 2 diabetes: Rosenstock et al. (Lancet, 2023) reported a phase 2 trial measuring glucose control in people with diabetes.

Wegovy's pivotal trial, STEP 1, is older and already underpins its approval. Wilding et al. (NEJM, 2021) reported weight loss outcomes in adults with overweight or obesity who received semaglutide compared to placebo over 68 weeks — the dataset the FDA reviewed before approving Wegovy for chronic weight management.

There is no published trial in the sources above that directly randomizes participants to retatrutide against Wegovy's semaglutide in the same study. Comparisons that appear online drawing a specific number against another are, at this point, comparisons across separate trials with separate populations, not a head-to-head result.

Semaglutide, Wegovy, and Ozempic: same molecule, two approvals

A detail that confuses a lot of searches: Wegovy and Ozempic are both semaglutide, both made by Novo Nordisk, approved for two different things. Wegovy received FDA approval for chronic weight management; Ozempic is approved for type 2 diabetes. They're the same active molecule under two brand names and two indications — not two different drugs.

Research-grade semaglutide sold outside the Wegovy or Ozempic brand is neither of those FDA-approved products. The FDA has published its own concerns about unapproved and compounded GLP-1 drugs sold outside the approved supply chain for weight loss, which is the relevant backdrop for anyone comparing a brand-name drug to a research compound of the same molecule.

Where this leaves a buyer comparing the two

If the question is "which one is approved," the answer doesn't require trial data: Wegovy is, retatrutide isn't. If the question is "which one has more mechanism behind it," retatrutide's triple-receptor design is the more recent idea in the GLP-1 research space, and it's part of why Eli Lilly moved it into phase 3 rather than stopping after phase 2. Tirzepatide, a dual GIP/GLP-1 agonist approved by the FDA as Zepbound and Mounjaro, sits mechanistically between the two — one receptor short of retatrutide, already approved unlike it.

None of this makes PeptoClinic's retatrutide a version of Wegovy, Ozempic, Zepbound, or Mounjaro. It's a separate research compound, analyzed for purity and sold at published prices, with its laboratory report available to check against the batch received. It is not approved by the FDA, and the development phase it's currently in is public record on ClinicalTrials.gov.